Cargando…
Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea
PURPOSE: M1 macrophages can promote corneal allograft rejection (CGR). Inhibiting M1 macrophage polarization by the JAK/STAT1 pathway may be a new strategy to prevent CGR. Tofacitinib, a potent pan-JAK inhibitor, can inhibit JAK/STAT activation. Here, we investigated the inhibitory effects of tofaci...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976928/ https://www.ncbi.nlm.nih.gov/pubmed/35353151 http://dx.doi.org/10.1167/tvst.11.3.34 |
_version_ | 1784680669117415424 |
---|---|
author | Yu, Jianfeng Li, Pengfei Li, Zhuang Li, Yingqi Luo, Jiawei Su, Wenru Liang, Dan |
author_facet | Yu, Jianfeng Li, Pengfei Li, Zhuang Li, Yingqi Luo, Jiawei Su, Wenru Liang, Dan |
author_sort | Yu, Jianfeng |
collection | PubMed |
description | PURPOSE: M1 macrophages can promote corneal allograft rejection (CGR). Inhibiting M1 macrophage polarization by the JAK/STAT1 pathway may be a new strategy to prevent CGR. Tofacitinib, a potent pan-JAK inhibitor, can inhibit JAK/STAT activation. Here, we investigated the inhibitory effects of tofacitinib on M1 macrophage polarization and its therapeutic effect on rat CGR. METHODS: Corneal allograft transplantation was performed and administrated with 0.3% tofacitinib in rats. The corneal allografts were assessed clinically. The corneas were detected for M1 macrophages, lymphatic vessels, and inflammatory cytokine expression using immunohistochemistry and real-time polymerase chain reaction (PCR). Dendritic cells (DCs) in ipsilateral cervical lymph nodes were detected by flow cytometry. The effect and mechanism of tofacitinib on macrophages were explored by real-time PCR, enzyme-linked immunoassay, and western blot analysis in vitro. RESULTS: The results showed that topical administration of 0.3% tofacitinib significantly prolonged corneal graft survival. Tofacitinib-treated corneal allografts displayed a proportionate decrease in M1 macrophages and reduced lymphatic vessel density with fewer DCs in rat ipsilateral cervical lymph nodes. Tofacitinib reduced the mRNA expression of inflammatory cytokines, including iNOS, MCP-1, TNF-α, IL-6, IL-1β, and VEGF-C, and inhibited STAT1 activation in rat corneal grafts. In addition, tofacitinib suppressed M1 macrophage polarization via STAT1 activation after IFN-γ and lipopolysaccharide stimulation in vitro. CONCLUSIONS: Tofacitinib could suppress M1 macrophage polarization and subsequently delay CGR by inhibiting STAT1 activation. The data indicate that tofacitinib is an effective drug for CGR. TRANSLATIONAL RELEVANCE: This study provided evidence that topical administration of 0.3% tofacitinib may be a novel clinical strategy to prevent CGR. |
format | Online Article Text |
id | pubmed-8976928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Association for Research in Vision and Ophthalmology |
record_format | MEDLINE/PubMed |
spelling | pubmed-89769282022-04-04 Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea Yu, Jianfeng Li, Pengfei Li, Zhuang Li, Yingqi Luo, Jiawei Su, Wenru Liang, Dan Transl Vis Sci Technol Article PURPOSE: M1 macrophages can promote corneal allograft rejection (CGR). Inhibiting M1 macrophage polarization by the JAK/STAT1 pathway may be a new strategy to prevent CGR. Tofacitinib, a potent pan-JAK inhibitor, can inhibit JAK/STAT activation. Here, we investigated the inhibitory effects of tofacitinib on M1 macrophage polarization and its therapeutic effect on rat CGR. METHODS: Corneal allograft transplantation was performed and administrated with 0.3% tofacitinib in rats. The corneal allografts were assessed clinically. The corneas were detected for M1 macrophages, lymphatic vessels, and inflammatory cytokine expression using immunohistochemistry and real-time polymerase chain reaction (PCR). Dendritic cells (DCs) in ipsilateral cervical lymph nodes were detected by flow cytometry. The effect and mechanism of tofacitinib on macrophages were explored by real-time PCR, enzyme-linked immunoassay, and western blot analysis in vitro. RESULTS: The results showed that topical administration of 0.3% tofacitinib significantly prolonged corneal graft survival. Tofacitinib-treated corneal allografts displayed a proportionate decrease in M1 macrophages and reduced lymphatic vessel density with fewer DCs in rat ipsilateral cervical lymph nodes. Tofacitinib reduced the mRNA expression of inflammatory cytokines, including iNOS, MCP-1, TNF-α, IL-6, IL-1β, and VEGF-C, and inhibited STAT1 activation in rat corneal grafts. In addition, tofacitinib suppressed M1 macrophage polarization via STAT1 activation after IFN-γ and lipopolysaccharide stimulation in vitro. CONCLUSIONS: Tofacitinib could suppress M1 macrophage polarization and subsequently delay CGR by inhibiting STAT1 activation. The data indicate that tofacitinib is an effective drug for CGR. TRANSLATIONAL RELEVANCE: This study provided evidence that topical administration of 0.3% tofacitinib may be a novel clinical strategy to prevent CGR. The Association for Research in Vision and Ophthalmology 2022-03-30 /pmc/articles/PMC8976928/ /pubmed/35353151 http://dx.doi.org/10.1167/tvst.11.3.34 Text en Copyright 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
spellingShingle | Article Yu, Jianfeng Li, Pengfei Li, Zhuang Li, Yingqi Luo, Jiawei Su, Wenru Liang, Dan Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea |
title | Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea |
title_full | Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea |
title_fullStr | Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea |
title_full_unstemmed | Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea |
title_short | Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea |
title_sort | topical administration of 0.3% tofacitinib suppresses m1 macrophage polarization and allograft corneal rejection by blocking stat1 activation in the rat cornea |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976928/ https://www.ncbi.nlm.nih.gov/pubmed/35353151 http://dx.doi.org/10.1167/tvst.11.3.34 |
work_keys_str_mv | AT yujianfeng topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea AT lipengfei topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea AT lizhuang topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea AT liyingqi topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea AT luojiawei topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea AT suwenru topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea AT liangdan topicaladministrationof03tofacitinibsuppressesm1macrophagepolarizationandallograftcornealrejectionbyblockingstat1activationintheratcornea |